文献速递消化、代谢与肾脏急症

乌帕替尼单药治疗活动性类风湿关节炎且甲氨蝶呤应答不足的患者(SELECT-MONOTHERAPY):一项随机、安慰剂对照、双盲3期研究

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
PubMed 文献 · Lancet · 2019-05-23
一句话结论甲氨蝶呤应答不足的活动性类风湿关节炎患者换用乌帕替尼单药(15 mg或30 mg每日一次)14周时ACR20和DAS28(CRP)≤3.2达标率均显著高于继续甲氨蝶呤。

SELECT-MONOTHERAPY在24个国家138个中心纳入648例符合2010年ACR-EULAR分类标准、甲氨蝶呤稳定治疗下仍活动性的类风湿关节炎成人患者,随机2:2:1:1换用乌帕替尼单药或继续原剂量甲氨蝶呤。第14周ACR20达标率:继续甲氨蝶呤组41%(89/216),乌帕替尼15 mg组68%(147/217),乌帕替尼30 mg组71%(153/215),两剂量组与继续甲氨蝶呤组比较p<0.0001。DAS28(CRP)≤3.2达标率:继续甲氨蝶呤组19%(42/216),15 mg组45%(97/217),30 mg组53%(114/215),p<0.0001。不良事件发生率三组相似(47%、47%、49%),带状疱疹在30 mg组为3%(6例)。

要点

  • 甲氨蝶呤应答不足的活动性类风湿关节炎患者,换用乌帕替尼15 mg或30 mg每日一次单药,第14周ACR20达标率分别为68%和71%,显著高于继续甲氨蝶呤的41%(p<0.0001)。
  • 第14周DAS28(CRP)≤3.2达标率:乌帕替尼15 mg组45%、30 mg组53%,继续甲氨蝶呤组19%(两剂量组p<0.0001)。
  • 不良事件发生率:继续甲氨蝶呤组47%(102例)、乌帕替尼15 mg组47%(103例)、30 mg组49%(105例),总体相似。
  • 带状疱疹报告例数:继续甲氨蝶呤组1例(<1%)、乌帕替尼15 mg组3例(1%)、30 mg组6例(3%)。
  • 研究中报告3例恶性肿瘤(继续甲氨蝶呤组1例[<1%]、乌帕替尼15 mg组2例[1%])、3例裁定主要不良心血管事件(15 mg组1例[<1%]、30 mg组2例[<1%])、1例裁定肺栓塞(<1%,15 mg组)和1例死亡(<1%,15 mg组,出血性卒中[动脉瘤破裂])。

适用人群与场景

  • 年龄≥18岁、符合2010年ACR-EULAR类风湿关节炎分类标准、尽管甲氨蝶呤稳定治疗仍为活动性类风湿关节炎的成人患者。
  • 研究在24个国家138个中心开展,患者随机分配至换用乌帕替尼单药或继续甲氨蝶呤。

诊断标准与关键阈值

  • 2010年ACR-EULAR类风湿关节炎分类标准。
  • 主要终点之一:第14周ACR20达标率(无应答者填补)。
  • 主要终点之二:第14周DAS28(CRP)≤3.2(低疾病活动度,无应答者填补)。

处置流程与药物剂量

  • 随机2:2:1:1分配:换用乌帕替尼单药(15 mg或30 mg每日一次)或继续原剂量甲氨蝶呤作为盲法研究药物。
  • 自第14周起,继续甲氨蝶呤组的患者按基线预设随机分配换用乌帕替尼15 mg或30 mg每日一次。

研究设计与关键结果

  • 研究类型:随机、安慰剂对照、双盲3期研究;样本量648例随机分配,598例(92%)完成第14周;24个国家138个中心。
  • 第14周ACR20:继续甲氨蝶呤组41%(89/216,95%CI 35-48),乌帕替尼15 mg组68%(147/217,95%CI 62-74),乌帕替尼30 mg组71%(153/215,95%CI 65-77);两剂量组与继续甲氨蝶呤组比较p<0.0001。
  • 第14周DAS28(CRP)≤3.2:继续甲氨蝶呤组19%(42/216,95%CI 14-25),乌帕替尼15 mg组45%(97/217,95%CI 38-51),乌帕替尼30 mg组53%(114/215,95%CI 46-60);两剂量组与继续甲氨蝶呤组比较p<0.0001。
  • 不良事件:继续甲氨蝶呤组47%(102例),乌帕替尼15 mg组47%(103例),乌帕替尼30 mg组49%(105例)。
  • 带状疱疹:继续甲氨蝶呤组1例(<1%),乌帕替尼15 mg组3例(1%),乌帕替尼30 mg组6例(3%)。
  • 3例恶性肿瘤:继续甲氨蝶呤组1例(<1%),乌帕替尼15 mg组2例(1%)。
  • 3例裁定主要不良心血管事件:乌帕替尼15 mg组1例(<1%),乌帕替尼30 mg组2例(<1%)。
  • 1例裁定肺栓塞(<1%,乌帕替尼15 mg组);1例死亡(<1%,乌帕替尼15 mg组,出血性卒中[动脉瘤破裂])。

证据类型、等级与局限

  • 证据类型:随机、安慰剂对照、双盲3期研究。
  • 作者结论:在该甲氨蝶呤应答不足人群中,乌帕替尼单药相比继续甲氨蝶呤在临床和功能结局方面显示统计学显著改善;安全性观察与既往乌帕替尼类风湿关节炎研究相似。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于甲氨蝶呤稳定治疗下仍活动性的类风湿关节炎成人患者,本研究显示换用乌帕替尼15 mg或30 mg每日一次单药14周时ACR20和DAS28(CRP)≤3.2达标率均显著高于继续甲氨蝶呤。
  • 研究中乌帕替尼30 mg组带状疱疹报告率为3%(6例),高于15 mg组的1%(3例)和继续甲氨蝶呤组的<1%(1例)。
  • 研究中报告了恶性肿瘤、主要不良心血管事件、肺栓塞和死亡事件,安全性观察与既往乌帕替尼类风湿关节炎研究相似。

指南或共识出处

  • SELECT-MONOTHERAPY研究,ClinicalTrials.gov注册号NCT02706951,由AbbVie Inc(美国)资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Upadacitinib, an oral Janus kinase (JAK)1-selective inhibitor, showed efficacy in combination with stable background conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with rheumatoid arthritis who had an inadequate response to DMARDs. We aimed to evaluate the safety and efficacy of upadacitinib monotherapy after switching from methotrexate versus continuing methotrexate in patients with inadequate response to methotrexate.

METHODS: SELECT-MONOTHERAPY was conducted at 138 sites in 24 countries. The study enrolled adults (≥18 years) who fulfilled the 2010 American College of Rheumatology (ACR)-European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis. Patients with active rheumatoid arthritis despite stable methotrexate were randomly assigned 2:2:1:1 to switch to once-daily monotherapy of of upadacitinib or to continue methotrexate at their existing dose as blinded study drug; starting from week 14, patients assigned to continue methotrexate were switched to 15 mg or 30 mg once-daily upadacitinib per prespecified random assignment at baseline. The primary endpoints in this report are proportion of patients achieving 20% improvement in the ACR criteria (ACR20) at week 14, and proportion achieving low disease activity defined as 28-joint Disease Activity Score using C-reactive protein (DAS28[CRP]) of 3·2 or lower, both with non-responder imputation at week 14. Outcomes were assessed in patients who received at least one dose of study drug. This study is active but not recruiting and is registered with ClinicalTrials.gov, number NCT02706951.

FINDINGS: Patients were screened between Feb 23, 2016, and May 19, 2017 and 648 were randomly assigned to treatment. 598 (92%) completed week 14. At week 14, an ACR20 response was achieved by 89 (41%) of 216 patients (95% CI 35-48) in the continued methotrexate group, 147 (68%) of 217 patients (62-74) receiving upadacitinib 15 mg, and 153 (71%) of 215 patients (65-77) receiving upadacitinib 30 mg (p<0·0001 for both doses vs continued methotrexate). DAS28(CRP) 3·2 or lower was met by 42 (19%) of 216 (95% CI 14-25) in the continued methotrexate group, 97 (45%) of 217 (38-51) receiving upadacitinib 15 mg, and 114 (53%) of 215 (46-60) receiving upadacitinib 30 mg (p<0·0001 for both doses vs continued methotrexate). Adverse events were reported in 102 patients (47%) on continued methotrexate, 103 (47%) on upadacitinib 15 mg, and 105 (49%) on upadacitinib 30 mg. Herpes zoster was reported by one (<1%) patient on continued methotrexate, three (1%) on upadacitinib 15 mg, and six (3%) on upadacitinib 30 mg. Three malignancies (one [<1%] on continued methotrexate, two [1%] on upadacitinib 15 mg), three adjudicated major adverse cardiovascular events (one [<1%] on upadacitinib 15 mg, two [<1%] on upadacitinib 30 mg), one adjudicated pulmonary embolism (<1%; upadacitinib 15 mg), and one death (<1%; upadacitinib 15 mg, haemorrhagic stroke [ruptured aneurysm]) were reported in the study.

INTERPRETATION: Upadacitinib monotherapy showed statistically significant improvements in clinical and functional outcomes versus continuing methotrexate in this methotrexate inadequate-responder population. Safety observations were similar to those in previous upadacitinib rheumatoid arthritis studies.

FUNDING: AbbVie Inc, USA.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019. PMID: 31130260. doi:10.1016/S0140-6736(19)30419-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。